CN101743474B - 检测心脏损伤的方法 - Google Patents

检测心脏损伤的方法 Download PDF

Info

Publication number
CN101743474B
CN101743474B CN200880021887.5A CN200880021887A CN101743474B CN 101743474 B CN101743474 B CN 101743474B CN 200880021887 A CN200880021887 A CN 200880021887A CN 101743474 B CN101743474 B CN 101743474B
Authority
CN
China
Prior art keywords
ctnt
cardiac
ctni
heart
levels
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200880021887.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN101743474A (zh
Inventor
X·彦
A·O·卡加诺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acorda Therapeutics Inc
Original Assignee
Acorda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acorda Therapeutics Inc filed Critical Acorda Therapeutics Inc
Priority to CN201410827283.7A priority Critical patent/CN104614510B/zh
Publication of CN101743474A publication Critical patent/CN101743474A/zh
Application granted granted Critical
Publication of CN101743474B publication Critical patent/CN101743474B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5061—Muscle cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
CN200880021887.5A 2007-05-10 2008-05-12 检测心脏损伤的方法 Expired - Fee Related CN101743474B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201410827283.7A CN104614510B (zh) 2007-05-10 2008-05-12 检测心脏损伤的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92854107P 2007-05-10 2007-05-10
US60/928,541 2007-05-10
PCT/US2008/006060 WO2008140814A1 (en) 2007-05-10 2008-05-12 Methods for detecting cardiac damage

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201410827283.7A Division CN104614510B (zh) 2007-05-10 2008-05-12 检测心脏损伤的方法

Publications (2)

Publication Number Publication Date
CN101743474A CN101743474A (zh) 2010-06-16
CN101743474B true CN101743474B (zh) 2015-06-03

Family

ID=40002559

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200880021887.5A Expired - Fee Related CN101743474B (zh) 2007-05-10 2008-05-12 检测心脏损伤的方法
CN201410827283.7A Expired - Fee Related CN104614510B (zh) 2007-05-10 2008-05-12 检测心脏损伤的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201410827283.7A Expired - Fee Related CN104614510B (zh) 2007-05-10 2008-05-12 检测心脏损伤的方法

Country Status (11)

Country Link
US (5) US8628929B2 (enExample)
EP (1) EP2153228A4 (enExample)
JP (5) JP5749490B2 (enExample)
CN (2) CN101743474B (enExample)
AU (1) AU2008251822B2 (enExample)
BR (1) BRPI0810631A2 (enExample)
CA (2) CA2686959C (enExample)
IN (1) IN2014MN01227A (enExample)
MX (2) MX2009012174A (enExample)
RU (1) RU2498309C2 (enExample)
WO (1) WO2008140814A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008251822B2 (en) 2007-05-10 2014-02-06 Acorda Therapeutics, Inc. Methods for detecting cardiac damage
EP3777878A1 (en) 2008-08-15 2021-02-17 Acorda Therapeutics, Inc. Compositions and methods for treatment during non-acute periods following cns neurological injury
US9198952B2 (en) 2008-09-22 2015-12-01 The Brigham And Women's Hospital, Inc. Compositions of and methods of using ligand dimers
EP2808339B1 (en) * 2008-11-28 2017-02-15 Zensun (Shanghai) Science & Technology, Co., Ltd. Neuregulin peptides and their use
US8835120B2 (en) * 2009-12-02 2014-09-16 Abbott Laboratories Assay for cardiac troponin-T (cTnT)
US8652788B2 (en) * 2009-12-02 2014-02-18 Abbott Laboratories Assay for diagnosis of cardiac myocyte damage
US9029328B2 (en) 2010-03-24 2015-05-12 The Brigham And Women's Hospital, Inc. Methods for cardioprotection and cardioregeneration with dimers of EGF family ligands
JP5676763B2 (ja) 2010-08-26 2015-02-25 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 動脈性高血圧症から心不全への初期移行の評価におけるバイオマーカーの使用
AU2014407088B2 (en) 2014-09-26 2021-09-23 Somalogic Operating Co., Inc. Cardiovascular risk event prediction and uses thereof
RU2585391C1 (ru) * 2014-12-19 2016-05-27 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования Чеченский государственный университет Способ иммунологического прогнозирования малых повреждений миокарда
US20180296642A1 (en) * 2015-09-25 2018-10-18 Douglas B. Sawyer Methods for treating cardiac injury
RU2648529C1 (ru) * 2016-12-27 2018-03-26 Федеральное государственное бюджетное образовательное учреждение высшего образования "Астраханский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Астраханский ГМУ Минздрава России) Способ оценки эффективности лекарственной терапии у взрослых пациентов с острой сердечной недостаточностью после операций на открытом сердце, получающих лечение методом экстракорпоральной мембранной оксигенации
RU2709458C2 (ru) * 2017-12-22 2019-12-18 Марина Александровна Чичкова Способ оптимизации ранней иммунологической диагностики осложнений чрескожного коронарного вмешательства у пациентов с ИБС
RU2722111C1 (ru) * 2019-12-30 2020-05-26 Федеральное государственное бюджетное образовательное учреждение высшего образования "Самарский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ ведения пациентов с хроническим лимфолейкозом в процессе полихимиотерапии по схеме fcr, направленный на предотвращение кардиотоксичности
RU2749552C1 (ru) * 2020-08-03 2021-06-15 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Способ отбора пациентов с длительно персистирующей формой фибрилляции предсердий на проведение эффективного катетерного лечения
RU2760242C1 (ru) * 2021-03-01 2021-11-23 федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр имени В.А. Алмазова" Министерства здравоохранения Российской Федерации Способ оценки повреждения миокарда и риска развития осложнений после операций на сердце в условиях искусственного кровообращения
CN113238060B (zh) * 2021-05-08 2022-10-11 迈克生物股份有限公司 用于预测或诊断心肌炎的试剂盒

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1655804A (zh) * 2002-05-24 2005-08-17 上海泽生科技开发有限公司 神经调节蛋白用于心血管疾病治疗的方法和组合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115554B1 (en) 1993-05-06 2006-10-03 Acorda Therapeutics, Inc. Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III
US5530109A (en) * 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US5716930A (en) 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US5324502A (en) * 1992-04-02 1994-06-28 Purdue Research Foundation Radiopharmaceuticals for imaging the heart
US6092695A (en) 1992-05-11 2000-07-25 Cytologix Corporation Interchangeable liquid dispensing cartridge pump
US6635249B1 (en) * 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
US6653249B1 (en) * 2000-05-25 2003-11-25 Penn Emblem Corporation Emblem having calendered fabric layer
GB0029154D0 (en) * 2000-11-30 2001-01-17 Lee Helen Signal enhancement with multiple labelled-antibodies
CN1267590C (zh) * 2004-06-11 2006-08-02 清华大学 一种用于组织修复的生长因子缓释体系的制备方法
CN1715926B (zh) * 2004-07-02 2011-08-17 上海泽生科技开发有限公司 神经调节蛋白突变体的应用
CA2614959A1 (en) 2005-07-14 2007-01-25 Myogen, Inc. Use of inhibitors of the ubiquitin proteasome pathway for increasing contractility of the heart
CA2658326C (en) * 2005-09-02 2013-04-23 Morehouse School Of Medicine Neuregulins for prevention and treatment of damage from acute assault on vascular and neuronal tissue
AU2008251822B2 (en) 2007-05-10 2014-02-06 Acorda Therapeutics, Inc. Methods for detecting cardiac damage
DE102007061117A1 (de) 2007-12-19 2009-06-25 Robert Bosch Gmbh Elektrische Kontaktierung
EP2603221A4 (en) 2010-08-13 2014-02-26 Univ Georgetown GGF2 AND METHOD FOR ITS APPLICATION

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1655804A (zh) * 2002-05-24 2005-08-17 上海泽生科技开发有限公司 神经调节蛋白用于心血管疾病治疗的方法和组合物

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
A novel transgenic mouse model reveals deregulation of the ubiquitin-proteasome system in the heart by doxorubicin.;Asangi R. K. Kumarapeli et al.;《The FASEB Journal》;20051231;第19卷;第2052页第3节和第4节 *
Cardiac troponin I and T alterations in hearts with severe left ventricular remodeling.;Vincent Ricchiuti et al.;《Clinical Chemistry》;19971231;第43卷;第990－995页 *
In vitro and in vivo examination of cardiac troponins as biochemical markers of drug-induced cardiotoxicity.;Adamcova et al.;《Toxicology》;20070726;第237卷;第218－228页 *
Phosphorylation-dependent degradation of p300 by doxorubicin-activated p38 mitogen-activated protein kinase in cardia cells.;Coralie Poizat et al.;《Molecular and Cellular Biology》;20051231;第25卷;图2C，2D,图11 *
Use of cardiac troponin T levels as an indicator of doxorubicin-induced cardiotoxicity.;Eugene H.Herman et al.;《Cancer Research》;19981231;第58卷;第195页右侧栏"血清cTnT水平"部分，第196页"cTnT免疫组织化学染色"部分，"讨论"部分第1－2段 *

Also Published As

Publication number Publication date
MX348082B (es) 2017-05-25
US8628929B2 (en) 2014-01-14
US20190269759A1 (en) 2019-09-05
JP5998171B2 (ja) 2016-09-28
JP2020176138A (ja) 2020-10-29
CA2965208A1 (en) 2008-11-20
EP2153228A1 (en) 2010-02-17
AU2008251822B2 (en) 2014-02-06
RU2498309C2 (ru) 2013-11-10
CN104614510A (zh) 2015-05-13
JP2017026622A (ja) 2017-02-02
US20110085976A1 (en) 2011-04-14
US20140378377A1 (en) 2014-12-25
AU2008251822A1 (en) 2008-11-20
JP2019010123A (ja) 2019-01-24
CN104614510B (zh) 2017-07-04
CA2686959C (en) 2017-06-13
CA2965208C (en) 2022-06-14
US9329171B2 (en) 2016-05-03
CN101743474A (zh) 2010-06-16
JP6978553B2 (ja) 2021-12-08
JP5749490B2 (ja) 2015-07-15
RU2009145695A (ru) 2011-06-20
US10258667B2 (en) 2019-04-16
JP2010527000A (ja) 2010-08-05
IN2014MN01227A (enExample) 2015-07-03
US11071770B2 (en) 2021-07-27
EP2153228A4 (en) 2010-08-04
MX2009012174A (es) 2010-03-30
JP2014122923A (ja) 2014-07-03
CA2686959A1 (en) 2008-11-20
US9757429B2 (en) 2017-09-12
US20180028610A1 (en) 2018-02-01
US20160263192A1 (en) 2016-09-15
JP6636402B2 (ja) 2020-01-29
WO2008140814A1 (en) 2008-11-20
BRPI0810631A2 (pt) 2017-05-09

Similar Documents

Publication Publication Date Title
CN101743474B (zh) 检测心脏损伤的方法
US20160061846A1 (en) Method for Evaluating Atherosclerotic Lesion, and Kit
US6884591B2 (en) Peripheral marker of blood brain barrier permeability
JP5347028B2 (ja) バイオマーカーとしてのＥＥＦ１Ａの使用およびＭｅｔＡＰ２阻害剤をスクリーニングするための方法
BR112020004136A2 (pt) fator de crescimento de fibroblastos modificado 21 (fgf-21) para uso nos métodos de tratamento de esteato-hepatite não alcoólica (nash)
AU2014202390B2 (en) Methods for detecting cardiac damage
CA3134620A1 (en) Use of kdm5a gene and atrx gene
JP2005304476A (ja) ポリアミン、アクロレインの含有量又はポリアミンオキシダーゼ活性又はその蛋白質量を指標とした脳卒中・無症候性脳梗塞の診断方法
JPWO2010093001A1 (ja) アルツハイマー病の診断方法および診断薬
EP2610620A1 (en) Histone deacetylase 10-inhibitor co-treatment in cancer
Paton Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy
Wagner Scientific highlights:“slices of life”
Murphy et al. The need for early markers in Alzheimer’s disease
Sana et al. The Role of Technetium Scintigraphy in the Non-Invasive Diagnosis of Transthyretin Cardiac Amyloidosis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150603

CF01 Termination of patent right due to non-payment of annual fee